SCHEMBL6527005

SCHEMBL6527005

c1ccc(Sc2ncc[nH]2)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 1/20 0.48
EHMT1 Q9H9B1 1/20 0.48
APOBEC3G Q9HC16 1/20 0.48
L3MBTL1 Q9Y468 3/20 0.46
ALDH1A1 P00352 4/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
NPSR1 Q6W5P4 2/20 0.42
GAA P10253 2/20 0.42
USP2 O75604 2/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
KDM4E B2RXH2 1/20 0.39
MTOR P42345 1/20 0.38
ADK P55263 1/20 0.38
NISCH Q9Y2I1 1/20 0.38
LMNA P02545 3/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
TSHR P16473 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1740306 0.76 TXN (0.45) ALDH1A1MEN1KMT2AMTORADK
SCHEMBL301719 0.76 EHMT2 (0.70) EHMT2EHMT1APOBEC3GL3MBTL1ALDH1A1
SCHEMBL5032699 0.76 MTOR (0.45) HPGDMTORADKNISCHHTT
SCHEMBL10891052 0.74 EHMT2 (0.67) EHMT2EHMT1APOBEC3GL3MBTL1ALDH1A1
Hydrochloric Acid SCHEMBL28385922 0.74 EHMT2 (0.67) EHMT2EHMT1APOBEC3GL3MBTL1ALDH1A1
SCHEMBL1036765 0.73 TXN (0.33) TXNTXNRD1
SCHEMBL10333796 0.73 PRKCI (0.42) L3MBTL1ALDH1A1NPSR1MAPTHPGD
SCHEMBL9531687 0.72 RAB9A (0.57) L3MBTL1ALDH1A1MEN1KMT2AMAPT
SCHEMBL7696085 0.71 HPGD (0.41) ALDH1A1KMT2AGAAMAPTHPGD
SCHEMBL924231 0.70 MTOR (0.36) MTORADKNISCHTAAR1TXN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906078-B2 Method of using (H+/K+) ATPase inhibitors as antiviral agents PHARMACIA CORPORATION (US) 2005-06-14 US disclosed
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents MOORMAN ALAN E (US) 2001-11-29 US disclosed
US-5945425-A ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE G.D. SEARLE & CO. (US) 1999-08-31 US disclosed
WO-1995029897-A1 METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS G.D. SEARLE & CO. (US) 1995-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents ATP4A, ATP1A1, ATP1A4 EHMT2 3557/4885EHMT1 2765/4885APOBEC3G 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.